Home > Boards > US Listed > Cannabis >

India Globalization Capital Inc. (IGC)

IGC RSS Feed
Add IGC Price Alert      Hide Sticky   Hide Intro
Moderator: Smilin_B, Femto99
Search This Board: 
Last Post: 5/23/2019 10:01:26 AM - Followers: 198 - Board type: Free - Posts Today: 0

165 FOLLOWERS AS OF 10/14/2018 
iBox Update 10/14/2018 11:35 CrazyKar123
 

India Globalization Capital, Inc. (NYSE MKT: IGC) is a first mover in developing a portfolio of products using cannabis-based "combination therapies" for the treatment of pain and other conditions.

IGC's strategy is exciting and unique in that it is aiming to become a leader in the phytocannabinoid-based combination therapy specialty pharmaceutical sector. This first-mover advantage can potentially be formidable as it begins clinical trials and further builds its patent portfolio

IGC recently exited its legacy businesses and currently holds international investments in land and in a hotel project.

 

Investment Highlights

• Building a patented portfolio of phytocannabinoid-based pharmaceutical and nutraceutical products for one of the world's fastest growing industries
• Positioning for first-mover advantage by developing novel therapies, applying for patents, and acquiring technologies from related industries
• Strategic alliance with International Pharma Trials provides expertise in the FDA process and pharma-trials

 


Development Pipeline

Through cutting-edge research, IGC is developing a product portfolio of phytocannabinoid-based therapies for the treatment of a wide range of life altering or life threatening indications, including neuropathic and cancer pain, epilepsy, end of life supportive care, adjunctive supportive therapies of chronic neurological and oncological diagnosis.


Target Markets

Attitudes toward cannabis have transformed substantially across the United States. Support for cannabis legalization is rapidly outpacing opposition; 53 percent of Americans believe cannabis should be made legal, compared with 44 percent supporting illegality of cannabis. Within this burgeoning market, IGC has identified key areas to which it can apply its phytocannabinoid-based therapies to address unmet medical needs.

 

Pain

The treatment of pain is a great challenge for health care professionals as it can often debilitate individuals in ways that affect their day-to-day functioning, which significantly impacts the nation's productivity and economy. The national cost of health care due to pain ranges from $560 billion to $635 billion. In addition, the health care cost attributed to the abuse of prescription opioids, closely related to pain, is approximately $25 billion.

A major disadvantage of using currently available drug therapies to treat chronic severe pain is that these opioid based drugs may lead to side effects like hallucinations, constipation, sedation, nausea, respiratory depression, and dysphoria.

IGC-501

IGC has applied for a U.S patent based on a novel therapy, IGC-502 indicated for seizures, using cannabinoid extracts. The therapy is administered, using a variety of delivery technologies, for indications in mammals such as dogs and cats. The therapy may also be useful in humans.

IGC expects to conduct metabolic profiling and apply to the FDA for trials over the next few years.

 

Epilepsy

Approximately 50 million people worldwide are affected by epilepsy (Sanders, 2003), a condition attributed to multiple factors. In dogs and cats, seizures are often caused by abnormal brain activity. They can be subtle or cause violent convulsions. Some seizures only occur once, but repeated seizures require treatment to prevent larger areas of the brain from becoming affected.

IGC-502

IGC has applied for a U.S patent based on a novel therapy, IGC-502 indicated for seizures, using cannabinoid extracts. The therapy is administered, using a variety of delivery technologies, for indications in mammals such as dogs and cats. The therapy may also be useful in humans.

IGC expects to conduct metabolic profiling and apply to the FDA for trials over the next few years.

 

Eating Disorders

Cachexia is a condition that accompanies severe illness such as cancer and results in the weakness and wasting away of the body. Approximately 1.3 million people in the United States are experiencing cachexia associated with cancer, multiple sclerosis, Parkinson's disease, HIV/AIDS, and other progressive illnesses. Notably, cancer-induced anorexia/cachexia is responsible for about 20% of all cancer deaths.

IGC-504 and IGC-506

Indicated for a variety of eating disorders, including cachexia, IGC-504 and IGC 506 are unique combination therapies that, if proven out by clinical trials, are expected to treat medical refractory epilepsy and eating disorders respectively, with lower side effects than conventional mono therapies. IGC-506 is being developed for both human and veterinary use.

 


Industry Partnerships

IGC has established a strategic alliance with International Pharma Trials, whose doctors and researchers have expertise in disorders of the central and peripheral nervous system as well as expertise in the FDA process and pharma-trials.

The company continues to seek information exchanges with medical cannabis dispensaries, research scientists, doctors, medical and business professionals, and biotech companies working in the cannabinoid space.

Leveraging its business model and collaborative research, IGC can help commercialize products while finding innovative ways of helping patients benefit from cannabinoids.

 


Leadership


Ram Mukunda, President, CEO and Director

Ram Mukunda has served as IGC's executive chairman, chief executive officer, and president since the company's inception on April 29, 2005. From January 1990 to May 2004, Mukunda served as founder, chairman, and chief executive officer of Startec Global Communications, an international telecommunications carrier focused on providing voice over Internet protocol (VOIP) services to emerging economies. Startec was the first pure play international long distance carrier. Mukunda was responsible for organizing, structuring and integrating a number of companies owned by Startec. Under Mukunda's tenure at Startec, the company made an IPO of its equity securities in 1997 on NASDAQ. Prior to Startec, Mr. Mukunda served as Strategic Planning Advisor at Intelsat, a communications satellite services provider.

Mukunda serves as an emeritus member on the Board of Visitors at the University of Maryland, School of Engineering. From 2001 to 2003, he was a council member at Harvard's Kennedy School of Government, Belfer Center of Science and International Affairs.

Mukunda is the recipient of several awards including, the 2013 University of Maryland's International Alumnus of the Year award, the 2001 Distinguished Engineering Alumnus Award, the 1998 Ernst & Young, LLP's Entrepreneur of the Year Award. He holds a B.S. degree in Electrical Engineering, a B.S degree in Mathematics, and a M.S. in Engineering from the University of Maryland.

John Cherin, CFO, Treasurer, PAO

John Cherin is a retired senior executive with international experience in assisting young companies. He has provided insight to top management and Board of Directors on strategic analysis and improvement of operating procedures in financial reporting and operations. From 1966 to 1997, Cherin gained his experience as a senior partner at Arthur Andersen while managing practices aimed at businesses in the US and overseas. In addition he founded and managed Cherin Global Consulting in 1997-2005 and the Cherin Group LLC in 2004 to date. He also served as CFO for IGC in its formative stages for the purpose of raising capital to enable IGC's launch in the post startup phase.

Cherin is a retired CPA, a graduate of Northeastern University class of 1966 and in 1967 was the Silver Medal Recipient from the Massachusetts Society of CPAs.

Claudia Grimaldi, General Manager, Director of Cabaran Ultima

Claudia Grimaldi is the general manager and director of IGC's project development and managing company in Malaysia. Grimaldi is responsible for coordinating the staff in various countries and ensuring timely and accurate regulatory compliance and statutory reporting. Prior to assuming her current role in 2013, she spent three years managing the office of the CEO.

Prior to IGC, Grimaldi worked in human resources and psychotherapy. She graduated Summa Cum Laude from Javeriana University, a top five University in Colombia, with a Bachelor of Arts in Psychology. She holds an MBA in General Management, graduating with Highest Honors, from Meredith College. Grimaldi is a member of Delta Mu Delta International Honor Society. She is also fluent in both English and Spanish.

 


India Globalization Capital
PO BOX 60642
Potomac, MD 20859-0642
Phone: (301) 983-0998
www.IGCinc.us

NetworkNewsWire
1324 Lexington Ave.
Suite 117
New York, NY 10128
Phone: (212) 418-1217
www.NetworkNewsWire.com

 

NetworkNewsWire is a moderator of this board. Please see disclaimer on the NetworkNewsWire website: https://www.networknewswire.com/disclaimer/





 








https://www.otcmarkets.com/stock/IGC/security









 











 

IGC
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
IGC News: IGC Announces Continued Educational Initiatives in Support of Hyalolex 04/22/2019 07:00:00 AM
IGC News: Current Report Filing (8-k) 03/27/2019 06:09:20 AM
IGC News: IGC Provides Corporate Updates 03/26/2019 09:00:00 PM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#8736  Sticky Note PATENT WIN!!! https://patentscope.wipo.int/search/en/detail.jsf?navig=previous&recNum=1&que Femto99 04/26/19 10:39:28 AM
#7084  Sticky Note IGC News = Re-Listed on the NYSE by Smilin_B 02/23/19 05:17:39 AM
#8752   Whats next? I think delisted again and paulatc 05/23/19 10:01:26 AM
#8751   Any news on marijuana investment can send the Femto99 05/16/19 11:09:41 AM
#8750   You are right, today is a good day Femto99 05/15/19 11:50:55 AM
#8749   PATIENCE beambe 05/01/19 01:54:14 PM
#8748   Last time someone sold a big order ~180k Femto99 05/01/19 01:44:41 PM
#8747   Looks like double bottom to me. This is Femto99 05/01/19 01:42:43 PM
#8746   Loading zone for me! Femto99 05/01/19 01:40:14 PM
#8745   I am just here for the MJ hype Femto99 04/30/19 08:16:34 PM
#8744   This time they managed to get $27m cash Femto99 04/30/19 08:13:09 PM
#8743   Well,igc seems like a low OS and low manofIsle 04/30/19 07:52:03 PM
#8742   good Volume beambe 04/28/19 04:18:28 PM
#8741   * * $IGC Video Chart 04-26-2019 * * ClayTrader 04/26/19 04:59:41 PM
#8740   The company is well positioned in this MJ/HEMP Femto99 04/26/19 11:21:33 AM
#8739   Yes you have. Also several positive SEC filings out. crudeoil24 04/26/19 11:14:22 AM
#8738   I have been calling it all week Femto99 04/26/19 11:10:14 AM
#8737   Very strong momo & fomo happening! crudeoil24 04/26/19 11:04:30 AM
#8736   PATENT WIN!!! https://patentscope.wipo.int/search/en/detail.jsf?navig=previous&recNum=1&que Femto99 04/26/19 10:39:28 AM
#8735   $IGC should be a $3 stock! Femto99 04/26/19 10:35:50 AM
#8734   IGC coming back! Femto99 04/26/19 10:35:34 AM
#8733   The price is so wrong Femto99 04/23/19 11:16:24 AM
#8732   away from what? paulatc 04/22/19 09:41:25 AM
#8731   4-20 is days away, I would expect some Femto99 04/17/19 07:49:17 PM
#8730   Buying low Femto99 04/15/19 12:33:01 PM
#8729   What is the consensus on the current float here? No-Quarter 04/12/19 10:41:36 AM
#8727   You nailed it :-). easymoney 04/10/19 06:46:12 AM
#8726   Why? Smilin_B 04/09/19 03:24:45 PM
#8725   I'm expecting something good today $3 weedtrader420 04/09/19 08:11:48 AM
#8724   Good call, I did not notice that. Sent Femto99 04/08/19 09:31:21 PM
#8723   Isn't it time to change the category to mijReswoh 04/08/19 08:20:07 PM
#8722   Lots of volume to just linger right around $2/share Smilin_B 04/08/19 05:50:15 PM
#8721   Something big happening weedtrader420 04/08/19 04:16:56 PM
#8720   Uno di questi giorni ci svegliamo con questo Bomber74 04/05/19 04:06:15 PM
#8719   IGC capital volumen spike for the news FDA considering Vlaotrd 04/02/19 12:06:12 PM
#8718   5% run up today. No news. Just random run. Iamfred69 04/02/19 11:58:58 AM
#8717   Yes but have you seen the volume over Smilin_B 03/29/19 04:29:40 PM
#8716   Volume so low today Femto99 03/29/19 10:56:21 AM
#8715   2 points.. surfer44 03/28/19 03:32:45 PM
#8714   60% of the volume is shorts volume. I Tanga011 03/28/19 02:58:44 PM
#8713   India Globalization Capital Announces Extension of Expiration Date Smilin_B 03/28/19 02:44:36 AM
#8712   All I can say with pretty decent certainty Smilin_B 03/28/19 02:42:27 AM
#8711   What is the strike price and expiration on surfer44 03/28/19 01:29:50 AM
#8710   Ram needs to start mentioning the cash they surfer44 03/28/19 01:22:54 AM
#8709   Yes it was trading above $3 in pre market. Kabuli 03/27/19 10:02:23 PM
#8708   Ram needs to start mentioning the cash they Smilin_B 03/27/19 06:32:08 PM
#8707   Don't know about the pre-market action. surfer44 03/27/19 06:25:42 PM
#8706   Was IGC really trading in the $3 range Smilin_B 03/27/19 06:04:15 PM
#8705   Here's a post. :-D surfer44 03/27/19 03:49:20 PM
#8704   Over 10 million dollars worth of stock exchanged Smilin_B 03/27/19 03:25:24 PM
#8703   Note the volume. Volume is huge today. The Smilin_B 03/27/19 12:24:58 PM
#8702   I only own the warrants Smilin_B 03/27/19 12:24:19 PM
PostSubject